Chinook Therapeutics has a Cash Ratio of 5.66. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Chinook Therapeutics's Cash Ratio or its related term are showing as below:
KDNY'
s Cash Ratio Range Over the Past 10 Years
Min: 4.62 Med: 7.81 Max: 12.3
Current: 5.66
During the past 4 years, Chinook Therapeutics's highest Cash Ratio was 12.30. The lowest was 4.62. And the median was 7.81.
KDNY's Cash Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.9
vs KDNY: 5.66
Chinook Therapeutics Cash Ratio Historical Data
The historical data trend for Chinook Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chinook Therapeutics's Cash Ratio
For the Biotechnology subindustry, Chinook Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chinook Therapeutics's Cash Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chinook Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Chinook Therapeutics's Cash Ratio falls into.
Chinook Therapeutics Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Chinook Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chinook Therapeutics (NAS:KDNY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Chinook Therapeutics Cash Ratio Related Terms
Thank you for viewing the detailed overview of Chinook Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Chinook Therapeutics (Chinook Therapeutics) Business Description
Chinook Therapeutics Inc is a clinical-stage biotechnology company. The products of the company are focused on rare, severe chronic kidney disorders. The clinical program is atrasentan, a potent and selective endothelin A receptor antagonist and currently conducting the phase 3 ALIGN trial of atrasentan for IgA nephropathy (IgAN) and the phase 2 AFFINITY basket trial for proteinuric glomerular diseases. The second product candidate, BION-1301, is an anti-APRIL monoclonal antibody and the third product candidate is CHK-336, an oral small-molecule LDHA inhibitor for the treatment of primary and idiopathic hyperoxaluria. It is incorporated in Delaware and is headquartered in Seattle, Washington.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KDNY has been successfully added to your 